Why MLTX is down from its high
Down 50% from its Jun 22, 2026 high.
- It filed a prospectus for an offering of shares on Jun 24, 2026, its newest of 2 offering filings.
Down 50% from its Jun 22, 2026 high.
Follow MLTX's trial news. Pro members can get an alert when MoonLake Immunotherapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 34.7% more shares than a year ago |
| Latest filing | 8-K, Nov 4 |
Tue Dec 1: Citi Global Healthcare Conference 2026Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed +0.9% on average, higher 1 of 4 times.
About 8 quarters
Chief Scientific Officer Kristian Reich sold 1,100 shares on Jul 27, under a planned sale. 13 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
MLTX is #224 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 224 |
Net income over four quarters: MLTX -$273M, VIR -$185M, OLMA -$236M, OCUL -$327M.
Expected to report Wed Feb 24, before the open (in 95 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.93 a share.
MLTX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The Company expects to have sufficient capital to fund its operating expenses and capital expenditure requirements to mid-2028.”
From its results filing (SEC filing · Nov 4)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | +1.4% | -1.2% | +7.3% |
| Aug 10, 2026 | -5.6% | -5.1% | -9.8% |
| May 11, 2026 | +6.9% | +10.4% | +2.9% |
RSI 44.3, MACD below signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
MLTX scores -7 today, which Breakaway calls Poor. It is #224 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 50% from its Jun 22, 2026 high. Cash lasts about 8 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
MLTX scores -7 today, which Breakaway calls Poor (below zero). That is #224 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MLTX's -7.
Expected to report Wed Feb 24, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. MLTX closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.